Writing the Integrated Benefit-Risk Evaluation Section in a PBRER

The Integrated Benefit-Risk Evaluation is where the PBRER moves from separate evidence streams to an overall regulatory and clinical judgement. The section should explain why the medicinal product's benefits do or do not continue to outweigh its risks under the authorised conditions of use, considering what has changed during the reporting interval and cumulatively.

Purpose and Regulatory Framework

The PBRER format is defined by ICH E2C(R2) and implemented in the EU PSUR framework through Commission Implementing Regulation (EU) No 520/2012 and GVP Module VII — Periodic safety update report (Rev. 1).

The integrated evaluation should draw on evidence already developed in the report. It is a synthesis section. Important new evidence should normally be presented and evaluated earlier rather than introduced here for the first time.

Integration Is More Than Summary

A summary says what the benefits are and what the risks are. An integrated evaluation explains how they relate in the clinical context.

For example, a serious toxicity may have very different implications when:

• treatment addresses a rapidly fatal disease with few alternatives;
• the toxicity is predictable and preventable;
• the toxicity occurs mainly in a subgroup that can be identified before treatment; or
• an equally effective and substantially safer alternative has become available.

The section should therefore interpret benefits and risks together rather than place two independent lists side by side.

Start From the Authorised Clinical Context

Benefit-risk conclusions should be anchored to the authorised indications and conditions of use relevant to the report.

The author should understand:

• the treated disease and its seriousness;
• the magnitude and durability of established benefit;
• clinically important alternatives;
• important identified and potential risks;
• relevant missing information;
• the populations in whom benefit or risk differs; and
• the risk-minimisation measures that form part of safe use.

A single global statement can be misleading when the balance differs materially by indication, line of therapy, age group or another clinically important subgroup.

What Changed During the Reporting Interval?

The integrated evaluation should focus on developments capable of altering the previous balance. These can include:

• a new important identified risk;
• materially changed frequency or severity of a known risk;
• resolution or escalation of an important potential risk;
• new evidence in a previously uncertain population;
• important effectiveness or efficacy information;
• a material change in therapeutic alternatives;
• evidence that risk minimisation is ineffective or effective; or
• a major change in authorised use.

Not every new piece of information changes the balance. The author should explain why the cumulative conclusion remains stable when that is the case.

Characterising Benefit

The benefit side should be based on clinically meaningful outcomes relevant to authorised use. Depending on the product, considerations may include:

• magnitude of effect;
• durability;
• quality and consistency of evidence;
• effectiveness in routine practice;
• impact on survival, symptoms, function or other important outcomes;
• performance in relevant subgroups; and
• unmet medical need.

The PBRER should not reproduce the original efficacy dossier. It should focus on benefit information relevant to the current benefit-risk judgement.

Characterising Risk

The risk side should focus on clinically important harms and uncertainties rather than the entire adverse-reaction profile.

Relevant considerations may include:

• seriousness and clinical consequences;
• frequency where reliable evidence permits estimation;
• reversibility;
• preventability or detectability;
• susceptible populations;
• dose or duration relationship;
• uncertainty surrounding potential risks; and
• effectiveness of existing risk-minimisation measures.

The author should distinguish the intrinsic risk from the practical consequences under current conditions of use. A serious risk may remain biologically unchanged while becoming more manageable because susceptible patients can be identified or monitoring can prevent severe outcomes.

Weighting Evidence Without Inventing a Numerical Formula

ICH E2C(R2) does not require a universal numerical score for benefits and risks. Qualitative scientific judgement is acceptable when the reasoning is explicit and grounded in evidence.

The author should therefore explain which factors carry the greatest clinical importance and why. A small increase in a reversible laboratory abnormality should not automatically receive the same weight as a rare but irreversible fatal event.

Likewise, a modest symptomatic benefit in a self-limiting disease may be weighed differently from substantial survival benefit in a life-threatening condition.

Population-Specific Benefit-Risk

An overall favourable balance can coexist with an unfavourable or less favourable balance in a defined subgroup.

Examples may include patients with:

• severe renal impairment;
• hepatic impairment;
• a particular genetic characteristic;
• pregnancy exposure;
• very advanced age;
• a specific co-medication; or
• a particular indication or treatment setting.

Where subgroup differences are clinically important, the integrated evaluation should explain them and connect them to any resulting contraindication, warning, dose adjustment or monitoring strategy.

Therapeutic Alternatives and Clinical Context

The meaning of a risk can change when the treatment landscape changes. A medicine with substantial toxicity may remain valuable when alternatives are ineffective or absent, but the same risk may become less acceptable after safer treatment options become established.

Therapeutic alternatives should be considered only to the extent relevant to authorised use and the current scientific judgement. The PBRER should not become a general treatment-guideline review.

Remaining Uncertainty

Uncertainty should be visible rather than hidden behind a binary favourable/unfavourable statement.

The author may need to explain:

• which potential risks remain unresolved;
• which populations remain insufficiently characterised;
• whether long-term data remain limited;
• whether rare outcomes remain imprecisely estimated; and
• what additional pharmacovigilance is expected to reduce uncertainty.

The question is whether the remaining uncertainty is acceptable within the current benefit-risk context and whether risk-management measures remain proportionate.

Risk Minimisation as Part of the Real-World Balance

The benefit-risk conclusion should reflect the medicine as authorised and managed, including relevant warnings, contraindications, monitoring and additional risk-minimisation measures.

However, risk minimisation should not be assumed effective merely because a programme exists. Where effectiveness data are available and material to the conclusion, the section should consider them.

If a measure is not working adequately, the integrated evaluation should explain whether this changes the practical acceptability of the risk or requires further action.

Changes in Benefit-Risk Versus Changes in Knowledge

An important distinction is whether new information changes the balance or merely improves characterisation.

For example:

• better definition of a known risk factor may improve safe use without changing the overall balance;
• resolution of a potential risk may reduce uncertainty without increasing therapeutic benefit;
• recognition of a serious unpreventable risk may materially worsen the balance; or
• new long-term effectiveness data may strengthen the benefit side while risks remain stable.

The section should state explicitly which of these has occurred.

A Practical Integration Method

A disciplined authoring approach is:

1. identify the authorised indications and relevant populations;
2. summarise the clinically important benefits that remain current;
3. identify the important risks and uncertainties that drive the present assessment;
4. determine what changed during the reporting interval;
5. assess whether risk minimisation changes the practical impact of harms;
6. consider whether the treatment landscape or exposed population changed materially;
7. explain subgroup differences where relevant;
8. state whether the overall balance changed and why; and
9. connect the conclusion to proposed or completed regulatory action.

This is recommended scientific-writing practice rather than a prescribed EMA scoring model.

Illustrative Example

Consider an oncology medicine with substantial survival benefit. During the interval, a rare immune-mediated neurological toxicity becomes an identified risk. The event can be severe, but early recognition and treatment appear to improve outcomes, and no comparable therapy provides the same benefit in the relevant line of treatment.

A weak conclusion would state:

A new risk was identified, but benefits continue to outweigh risks.

A stronger integrated evaluation would explain the magnitude and clinical importance of the established benefit, the rarity and severity of the newly identified toxicity, the evidence supporting early recognition and management, the patient population affected, and why the updated conditions of use preserve a favourable overall balance. Any residual uncertainty should also be stated.

Potential Writing Failure Modes

The following are illustrative writing failures, not inspection findings.

Cross-Section Reconciliation

Before finalisation, reconcile the integrated evaluation with:

• the Executive Summary;
• Actions Taken for Safety Reasons;
• Changes to Reference Safety Information;
• signal evaluations;
• Evaluation of Risks and New Information;
• Benefit Evaluation;
• the RMP where relevant; and
• Conclusions and Actions.

The integrated section should not contradict a major action described elsewhere. If a serious restriction was implemented during the interval, the benefit-risk discussion should explain how that action relates to the current balance.

Practical Review Checklist

1. Are the authorised indications and populations clear?
2. Are the clinically important benefits current and appropriately characterised?
3. Are the risks discussed in proportion to their clinical importance?
4. Is new evidence distinguished from long-established knowledge?
5. Are important uncertainties explicit?
6. Is reliable quantitative evidence used where available without false precision?
7. Are subgroup differences addressed where relevant?
8. Is risk-minimisation effectiveness considered when material?
9. Are therapeutic alternatives considered only where they affect the judgement?
10. Does the section explain whether the balance changed and why?
11. Is all major evidence traceable to earlier sections?
12. Are resulting actions consistent with the conclusion?

Relationship With Other QPPV.com PBRER Articles

For the overall report logic see [[understanding-the-structure-of-a-pbrer]]. Detailed risk evaluation is covered in [[writing-the-evaluation-of-risks-and-new-information-section-in-a-pbrer]]. The opening synopsis is covered in [[writing-the-executive-summary-in-a-pbrer]], while the final regulatory translation is addressed in [[writing-the-overall-conclusion-section-in-a-pbrer]]. See also [[pbrer-guide]] and [[how-to-write-a-pbrer]].

Key Takeaways

Integrated benefit-risk evaluation is a scientific judgement about authorised use, not a numerical subtraction of risks from benefits and not a summary of preceding sections.

The strongest evaluation connects clinically important benefit, important harms, uncertainty, patient population, treatment context and risk minimisation in one transparent argument.

New information can improve characterisation without changing the overall balance. When the balance does change, the evidence responsible for that change should be explicit.

A favourable conclusion should explain why it remains favourable and under which conditions of use, while acknowledging material residual uncertainty.

References

1. International Council for Harmonisation. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER). Step 4, 15 November 2012.
2. International Council for Harmonisation. ICH E2C(R2) Questions and Answers. Last update 31 March 2014.
3. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VII — Periodic safety update report (Rev. 1). EMA/816292/2011 Rev. 1.
4. European Medicines Agency. Periodic safety update reports (PSURs). Current procedural guidance.
5. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module V — Risk management systems (Rev. 2). EMA/838713/2011 Rev. 2.
6. European Union. Commission Implementing Regulation (EU) No 520/2012, as amended.
7. European Union. Directive 2001/83/EC, as amended.
8. European Union. Regulation (EC) No 726/2004, as amended.

Regulatory Note

This article explains scientific authoring of the integrated benefit-risk section of the PBRER/PSUR. ICH E2C(R2) and GVP Module VII require an integrated cumulative benefit-risk evaluation but do not prescribe a universal numerical weighting model. As of 9 September 2026, GVP Module VII Rev. 1 remains the published EMA module; current procedural guidance should be checked for live submissions.